Zimmer Biomet

Eric Huppi, Former Zimmer Biomet Executive, Joins Movemedical

Retrieved on: 
Tuesday, February 1, 2022
Biotechnology, Medical Devices, Health, Technology, Software, Growth, CEO, Leadership, Rehabilitation, Loss, Automation, Health, Software as a service, Forecasting, ERP, Partnership, National Directorate for Personal Data Protection, Zimmer Biomet, Knowledge, COO, Industry, Pleasure, LinkedIn, ZB

Eric Huppi was recently appointed as the new Vice President of Product and Partner Experience at Movemedical, the leading medical device operations automation platform.

Key Points: 
  • Eric Huppi was recently appointed as the new Vice President of Product and Partner Experience at Movemedical, the leading medical device operations automation platform.
  • Mr. Huppi spent 8 years at Zimmer Biomet progressing in responsibility, and for his last three years there was the National Director of Sales Operations & Logistics.
  • Most recently, Eric Huppi served as the COO of IncludeHealth, a digital health & wellness company that optimizes patient care by pairing HIPAA-compliant cloud software with inclusive rehabilitation equipment.
  • Bo Molozcnik, Founder and CEO of Movemedical, announces that We are more than excited for the knowledge, experience, and leadership that Eric brings to our customer partners.

Zimmer Biomet Receives 100 Percent Rating on 2022 Human Rights Campaign Foundation's Corporate Equality Index

Retrieved on: 
Thursday, January 27, 2022
NYSE, Corporate Equality Index, Artificial intelligence, Quality of life, Patient, Culture, Life, Human Rights Campaign, Pain, Twitter, GLMA: Health Professionals Advancing LGBTQ Equality, HRC, Zimmer Biomet, CEO, Solution, LGBTQ, Health, Leadership, Management

WARSAW, Ind., Jan. 27, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has earned a 100 percent rating on the 2022 Human Rights Campaign (HRC) Foundation's Corporate Equality Index , globally recognized, national benchmarking survey on corporate policies, practices and benefits pertinent to LGBTQ+ workplace equity.

Key Points: 
  • WARSAW, Ind., Jan. 27, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has earned a 100 percent rating on the 2022 Human Rights Campaign (HRC) Foundation's Corporate Equality Index , globally recognized, national benchmarking survey on corporate policies, practices and benefits pertinent to LGBTQ+ workplace equity.
  • "Zimmer Biomet is committed to creating, supporting and celebrating diverse and equal workplaces and communities, and we are proud to have achieved this recognition from the Human Rights Campaign Foundation," said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet.
  • The Corporate Equality Index rates companies on detailed criteria under four central pillars: non-discrimination policies, equitable employment benefits for LGBTQ workers and their families, supporting an inclusive culture and corporate social responsibility.
  • Earning a perfect score on the HRC Corporate Equality Index also rewards Zimmer Biomet with a Best Place to Work for LGBTQ Equality recognition as part of this year's national benchmarking survey and report.

Gluckstein Lawyers Launches Canada-Wide Class-action Lawsuit After Elbow Surgery Device Failures

Retrieved on: 
Wednesday, January 26, 2022
People, Employment, Zimmer, Swelling, Psychological injury, Class, Life, Instability, Pain, Motion, Lawyer, Injury, Inflammation, Elbow, Zimmer Biomet, Health insurance

TORONTO, Jan. 26, 2022 /CNW/ -Gluckstein Lawyers has commenced a proposed class-action personal injury lawsuit alleging that the ExploR Modular Radial Head System medical device used in elbow surgeries across Canada resulted in permanent injuries and the need for corrective surgery.

Key Points: 
  • TORONTO, Jan. 26, 2022 /CNW/ -Gluckstein Lawyers has commenced a proposed class-action personal injury lawsuit alleging that the ExploR Modular Radial Head System medical device used in elbow surgeries across Canada resulted in permanent injuries and the need for corrective surgery.
  • The plaintiff alleges the device was improperly designed, manufactured and tested, resulting in the screw backing out into the elbow.
  • "People rely on medical products to return to the life they were living before they were injured," says Class-action lawyer Jordan Assaraf of Gluckstein Lawyers.
  • If you have experienced pain or complications from the ExploR Modular Radial Head System and would like further information about the lawsuit, please contact Gluckstein Lawyers at (416) 408-4252 or visit our website .

Hyalex Orthopaedics Appoints Carl Vause, Orthopaedic Industry Veteran, as Chief Executive Officer and President and Names Mike Hawkins, Ph.D., Chief Technical Officer

Retrieved on: 
Tuesday, January 25, 2022
Research, Patient, American Academy of Orthopaedic Surgeons, Cartilage, Smith & Nephew, Zimmer Biomet, Soft robotics, Science, Smith, Material, Sports medicine, CEO, American Academy, William H. Harris (orthopaedic surgeon), Solution, Joint, View, American Orthopaedic Society for Sports Medicine, Congress, Multimedia, Management, Medical device, Dentistry, Pharmaceutical industry

Mr. Vause, who succeeds Hyalex's interim president, Michael Hawkins, Ph.D., has also been appointed to the company's board of directors.

Key Points: 
  • Mr. Vause, who succeeds Hyalex's interim president, Michael Hawkins, Ph.D., has also been appointed to the company's board of directors.
  • Additionally, Dr. Hawkins has been named chief technical officer and will continue to serve as a director on the company's board.
  • Mr. Vause brings to Hyalex a track record of success in developing and launching groundbreaking orthopaedic products to the sports medicine market.
  • Prior to joining Hyalex, he served as vice president, marketing at CONMED Orthopedic Solutions, CEO of Soft Robotics and global joint repair franchise leader at Smith & Nephew.

Zimmer Biomet Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of ZimVie; ZimVie to Host Investor Day on February 7

Retrieved on: 
Friday, January 21, 2022
Patient, SEC, Vie, NYSE, Dental, Solution, Leadership, Form 10-K, Q&A, Health, U.S. Securities and Exchange Commission, Culture, Artificial intelligence, Twitter, Zimmer Biomet, Life, Organization, Cryptocurrency, Spine

The Form 10 includes detailed information about ZimVie, such as historic financial information, a description of ZimVie's business and strategy, and other legal and financial disclosures.

Key Points: 
  • The Form 10 includes detailed information about ZimVie, such as historic financial information, a description of ZimVie's business and strategy, and other legal and financial disclosures.
  • In addition, ZimVie will host a virtual Investor Day on Monday, February 7, 2022 from 11:00 a.m. to approximately 3:00 p.m. Eastern Time.
  • Zimmer Biomet announced in February 2021 its intent to form a new independent, publicly traded company to optimize resource allocation and drive toward market leadership.
  • "Zim" derives from Zimmer Biomet, the new company's roots and "Vie" is the French word for "life," symbolizing the future.

Stimwave Technologies Announces Chris Valois as Chief Marketing and Strategy Officer

Retrieved on: 
Friday, January 7, 2022
Biotechnology, General Health, Health, Medical Devices, Chronic pain, Strategic planning, University, Augustus A. Bird, Freedom, HF, Growth, Patient, Spinal cord, Physician, SCS, Medtronic, Hyperreflexia, Master of Business Administration, Zimmer Biomet, University of St. Thomas (Texas), General manager, Peripheral nerve stimulation, Gustav Tornier, Olympus, Spine, Marketing, FDA, St. Jude Medical, Pain, Technology, FH, Brain, Industry, PNS, Business administration, Management, Medical device

Today Stimwave Technologies announced the appointment of Chris Valois as its Chief Marketing and Strategy Officer, effective January 1, 2022.

Key Points: 
  • Today Stimwave Technologies announced the appointment of Chris Valois as its Chief Marketing and Strategy Officer, effective January 1, 2022.
  • This is a key turning point in the continued commercialization of our innovative spinal cord and peripheral nerve stimulation platforms, said Aure Bruneau, Chief Executive Officer.
  • We're confident that Chris will help propel Stimwave Technologies to the next level.
  • I am very excited to be joining the Stimwave Technologies team at this critical inflection point in our growth, said Mr. Valois.

Worldwide Prosthetic Industry to 2026 - by Technology Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021
General Health, Automotive Manufacturing, Medical Devices, Manufacturing, Health, Compliance, Zimmer Biomet, Smith, Technology, Bionics, Somatosensory system, Incidence, Renewable energy, Dentistry, Risk management, Biomet

In prosthetic market, various technologies such as conventional, electric powered, and hybrid orthodontic prosthetics are used in the disabled adults and disabled children applications.

Key Points: 
  • In prosthetic market, various technologies such as conventional, electric powered, and hybrid orthodontic prosthetics are used in the disabled adults and disabled children applications.
  • This report analyzes technology maturity, degree of disruption, competitive intensity, market potential, and other parameters of various technologies in the prosthetic market.
  • The study includes technology readiness, competitive intensity, regulatory compliance, disruption potential, trends, forecasts and strategic implications for the global prosthetic technology by application, technology, and region.
  • This report answers the following 9 key questions:
    Q.1 What are some of the most promising and high-growth technology opportunities for the prosthetic market?

Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

Retrieved on: 
Tuesday, December 14, 2021
Biotechnology, General Health, Health, Medical Devices, Stryker Corporation, Forward-looking statement, Executive, Uncertainty, Babson College, European Economic Area, Colgate University, SI, Board, Spine, IPO, American, Back pain, Industry, Nasdaq, James Madison University, Restore Our Future, Multifidus muscle, Director, Risk, Zimmer Biomet, B.A, Patient, Leadership, Anatomy, Lists of diseases, Management, ReActiv8®, Mainstay Medical, REACTIV8®, MAINSTAY MEDICAL

Mainstay Medical Holdings plc today announced the appointment of two new independent members to the companys board of directors, Jeffrey Dunn and Eric Major.

Key Points: 
  • Mainstay Medical Holdings plc today announced the appointment of two new independent members to the companys board of directors, Jeffrey Dunn and Eric Major.
  • We are pleased to welcome these two transformational business leaders as new independent directors on the Board, said David Brabazon, Chairman of the Mainstay Board of Directors.
  • Both Jeff and Eric have strong track records of success leading medical device companies focused on back pain from the launch phase through maturity.
  • Mr. Dunn co-founded the company and served as its President, Chief Executive Officer and Chairman of the Board of Directors from 2008 until April 2021.

Valencia Technologies Strengthens Leadership Team with Key Appointments

Retrieved on: 
Monday, November 29, 2021
Bionics, Senior, Bachelor, Rutgers Graduate School of Education, Medtronic, Board of directors, Board, Interim, Food and Drug Administration, Communication, Overactive bladder, BPH, Private Securities Litigation Reform Act, Product, Bachelor of Engineering, SNS, University, Health policy, TUNA, Teleflex, Cochlear, Zimmer Biomet, Market for corporate control, Business administration, Vidame, MBA, University of Michigan, Boston Scientific, Female, Education, Sonova, FDA, Health administration, Management, Electricity, Quality engineering, Hotel manager, University of Northern Colorado, Global marketing, Bachelor of Business Administration, Western Michigan University, Manufacturing engineering

VALENCIA, Calif., Nov. 29, 2021 /PRNewswire/ -- Valencia Technologies, a privately held company, today announced the expansion of its leadership team with the appointments of Jerry Schloffman as Chief Commercial Officer, Jim Crines as Interim Chief Financial Officer, Arthur Rasconas Senior Vice President of Operations, and Ann Decker as Vice President of Reimbursement and Health Policy.

Key Points: 
  • VALENCIA, Calif., Nov. 29, 2021 /PRNewswire/ -- Valencia Technologies, a privately held company, today announced the expansion of its leadership team with the appointments of Jerry Schloffman as Chief Commercial Officer, Jim Crines as Interim Chief Financial Officer, Arthur Rasconas Senior Vice President of Operations, and Ann Decker as Vice President of Reimbursement and Health Policy.
  • He joins Valencia from Sycle where he served as President of the Audiology and Hearing Aid Practice Management Software business.
  • Prior to his last role at Cochlear, Mr. Schloffman served as Chief of Clinical Operations at Valencia.
  • Valencia Technologies Corporation ("Valencia"), a private medical technology company located in Valencia, California, designed and manufactured its eCoin device for the treatment of urgency urinary incontinence (UUI).

Xenter, Inc. Appoints Tony Collins, Former Zimmer Biomet Group CFO, as Chief Financial Officer

Retrieved on: 
Monday, October 18, 2021
Software, Biotechnology, Pharmaceutical, Internet, Health, Medical Devices, Data Management, Technology, Goal, Chief executive officer, Health technology, Industry, Theory of multiple intelligences, Zimmer Biomet, Physician, Engineering, AI, Knowledge, Medicine, Patient, Accounting, Market for corporate control, Collection, CEO, Biomarker, Therapy, Medical device, Management

Following the formation of the Xenter Therapeutics and Xenter Medical Technologies business units, Xenter, Inc. ( XenterMD.com ), the first purpose-built medical device-data-drug technologies company, today announced the appointment of Tony Collins as Chief Financial Officer.

Key Points: 
  • Following the formation of the Xenter Therapeutics and Xenter Medical Technologies business units, Xenter, Inc. ( XenterMD.com ), the first purpose-built medical device-data-drug technologies company, today announced the appointment of Tony Collins as Chief Financial Officer.
  • Tony Collins served as Group Chief Financial Officer at Zimmer Biomet since 2019 where he was responsible for all strategic and financial planning, business development, accounting, and internal controls for over $8B in revenues across all global business units.
  • Additionally, Collins held numerous other financial leadership positions at Zimmer Biomet, including Vice President, Finance, Corporate Controller and Chief Accounting Officer and Vice President Finance for Global Operations and Supply Chain.
  • Prior to Zimmer Biomet, Collins held several executive leadership positions with Guidant/Boston Scientific, including Chief Financial Officer of Guidant Japan.